US2021187448A1PendingUtilityA1

Crosslinked protein-based separation membrane and application thereof

55
Assignee: UNIV SHAANXI NORMALPriority: May 14, 2018Filed: May 7, 2019Published: Jun 24, 2021
Est. expiryMay 14, 2038(~11.8 yrs left)· nominal 20-yr term from priority
B01D 69/1071B01D 69/1251B01D 2325/0283B01D 67/0093B01D 71/48B01D 61/243B01D 71/441B01D 69/144B01D 67/0034B01D 67/0006B01D 2325/04B01D 2323/40B01D 2323/38B01D 69/02B01D 2323/30B01D 71/44B01D 2325/02B01D 69/10B01D 67/00931
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A crosslinked protein-based separation membrane and application thereof. The separation membrane is formed by attaching a crosslinked protein nanomembrane to a porous membrane, the crosslinked protein nanomembrane is formed by crosslinking a two-dimensional nanomembrane which is formed by phase transition of a protein with a crosslinking agent, the separation membrane contains a dense surface layer and a support layer, the dense surface layer is the crosslinked protein nanomembrane, and the support layer is the porous membrane; the protein is any one of lysozyme, bovine serum albumin, insulin, and α-lactalbumin; the crosslinked protein-based separation membrane has a good biocompability, may serve as a dialysis membrane for blood purification, and has a higher retention ratio for large molecular proteins.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A crosslinked lysozyme-based dialysis membrane, wherein the dialysis membrane is formed by attaching a crosslinked lysozyme nanomembrane to a PET nuclear track membrane, the crosslinked lysozyme nanomembrane is formed by crosslinking a two-dimensional nanomembrane which is formed by phase transition of a lysozyme with a glutaraldehyde, the dialysis membrane contains a dense surface layer and a support layer, the dense surface layer is the crosslinked lysozyme nanomembrane, and the support layer is the PET nuclear track membrane;
 a method of forming a lysozyme two-dimensional nanomembrane by phase transition of the lysozyme comprises: adjusting a pH value of a 10-100 mmol/L 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid buffered solution of tris(2-carboxyethyl) phosphine to 6.0-8.0 by using NaOH to get an adjusted solution, then mixing the adjusted solution with a 1-30 mg/mL 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid buffered solution of the lysozyme in an isovolumetric manner to get a mixed solution, spreading the mixed solution to a whole surface of a substrate directly, incubating at room temperature for 2-6 hours, forming a layer of the lysozyme two-dimensional nanomembrane on a gas-liquid interface of a liquid on the substrate;   a method of crosslinking the lysozyme two-dimensional nanomembrane which is formed by phase transition of the lysozyme with the glutaraldehyde comprises: transferring the lysozyme two-dimensional nanomembrane to a glutaraldehyde aqueous solution with a mass fraction of 0.2%-2% for crosslinking for 2-6 hours at room temperature.   
     
     
         16 . The crosslinked lysozyme-based dialysis membrane according to  claim 15 , wherein a diameter of the PET nuclear track membrane is 25 mm, a thickness of the PET nuclear track membrane is 12 μm, a pore size of the PET nuclear track membrane is in a range of 1-10 μm. 
     
     
         17 . Use of the crosslinked lysozyme-based dialysis membrane in the separation of mixed proteins according to  claim 15 , wherein the mixed proteins are bovine serum albumin and insulin, or muscle hemoglobin and insulin. 
     
     
         18 . Use of the crosslinked lysozyme-based dialysis membrane in the separation of mixed dyes according to  claim 15 , wherein the mixed dyes are methyl blue and methyl orange, or methyl blue and Rhodamine B. 
     
     
         19 . Use of the crosslinked lysozyme-based dialysis membrane in the removal of urotoxin according to  claim 15 , wherein the urotoxin is any one of urea, creatinine, β-microglobulin and indoxyl sulfate.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.